BRAF and colorectal carcinoma: The ineffectiveness of EGFR-antibodies in CRC patients with mutations in the KRAS, NRAS or BRAF genes [149], requires the search of alternate treatments such as the use of DDR1 inhibitors like Nilotinib, which has demonstrated to be effective to inhibit the invasive and metastatic behavior of CRC through a RAS-independent mechanism [92].